Dfn-15
Allodynia
Hartford HospitalPhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Allodynia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dextromethorphan Brigham and Women's Hospital | Phase 2 | B |
LIDOCAINE Brigham and Women's Hospital | Phase 2 | B |
Xeomin® University of Manitoba | Phase 2 | CCC |
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →